Efficacy of Acoramidis in Adults With Transthyretin Amyloid Cardiomyopathy: Propensity Score Comparison Between a Single-Arm Open-Label Phase 3 Trial in Japan and a Global Double-Blind Phase 3 Trial
{{output}}
Background: Acoramidis is an oral, highly selective transthyretin (TTR) stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM). This analysis compared efficacy outcomes over a 30-month period between acoramidis-tr... ...
